根据最新披露的合并方案,在交易完成后,原Boundless Bio的股东预计将持有合并后公司3.7%的股份,而原Serapha的股东则预计将持有合并后公司96.3%的股份。这一股权分配比例明确了双方在合并后实体中的权益结构。
根据最新披露的合并方案,在交易完成后,原Boundless Bio的股东预计将持有合并后公司3.7%的股份,而原Serapha的股东则预计将持有合并后公司96.3%的股份。这一股权分配比例明确了双方在合并后实体中的权益结构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.